The changing picture of community acquired urinary tract infections in the US: a daunting prospect.

INTRODUCTION: Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, yet rising antimicrobial resistance is rapidly eroding the effectiveness of standard oral therapies. Resistance to fluoroquinolones and trimethoprim-sulfamethoxazole exceeding 40% among uropathogenic Escherichia coli, driven by multidrug-resistant and ESBL-producing Enterobacterales strains such as ST131, is fueling increased reliance on parenteral agents and hospitalizations.

AREAS COVERED: This commentary reviews the current US epidemiology of UTI, including the growing burden of ESBL-producing Enterobacterales and the pandemic ST131 lineage, and summarizes resistance patterns among key uropathogens. It highlights oral agents approved or under review in the US, specifically pivmecillinam, sulopenem, and gepotidacin for uncomplicated UTI, and tebipenem pivoxil hydrobromide, which if approved would represent the first oral carbapenem for selected complicated UTIs, and discusses stewardship principles for community UTI management. Established first-line agents are referenced in the context of resistance trends but are not reviewed comprehensively.

EXPERT OPINION: Recently approved or emerging oral agents offer a meaningful opportunity to reduce intravenous carbapenem dependence and avoid hospitalizations, though uptake may be constrained by cost, limited post-marketing experience, and stewardship concerns. Judiciously deployed, these agents could reduce the burden of multidrug-resistant UTI, contingent on further real-world and pharmacoeconomic evidence.